van der Velden Fabian J S, Gennery Andrew R, Emonts Marieke
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
Great North Children's Hospital, Paediatric Immunology, Infectious Diseases and Allergy, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
Front Pediatr. 2022 Mar 10;10:828569. doi: 10.3389/fped.2022.828569. eCollection 2022.
This study aims to assess the performance of biomarkers used for the prediction of bacterial, viral, and fungal infection in immunocompromised children upon presentation with fever.
We performed a literature search using PubMed and MEDLINE and In-Process & Other Non-indexed Citations databases. Cohort and case-control studies assessing biomarkers for the prediction of bacterial, viral, or fungal infection in immunocompromised children vs. conventional microbiological investigations were eligible. Studies including adult patients were eligible if pediatric data were separately assessable. Data on definitions used for infections, fever, and neutropenia and predictive values were collected. Risk of bias was assessed with the Quality Assessment of Diagnostic Accuracy Studies-2 tool.
Fifty-two studies involving 13,939 febrile episodes in 7,059 children were included. In total, 92.2% were in cancer patients ( = 48), and 15.7% also included hematopoietic stem cell transplantation patients ( = 8). Forty-three biomarkers were investigated, of which 6 (CRP, PCT, IL-8, IL-6, IL-10, and TNFα) were significantly associated with bacterial infection at admission, studied in multiple studies, and provided predictive data. Literature on the prediction of viral and fungal infection was too limited. Eight studies compared C-reactive protein (CRP) and procalcitonin (PCT), with PCT demonstrating superiority in 5. IL-6, IL-8, and IL-10 were compared with CRP in six, four, and one study, respectively, with mixed results on diagnostic superiority. No clear superior biomarker comparing PCT vs. IL-6, IL-8, or IL-10 was identified.
There is great heterogeneity in the biomarkers studied and cutoff values and definitions used, thus complicating the analysis. Literature for immunocompromised children with non-malignant disease and for non-bacterial infection is sparse. Literature on novel diagnostics was not available. We illustrated the challenges of diagnosing fever adequately in this study population and the need for improved biomarkers and clinical decision-making tools.
本研究旨在评估用于预测免疫功能低下儿童发热时细菌、病毒和真菌感染的生物标志物的性能。
我们使用PubMed、MEDLINE以及“在研及其他非索引引文”数据库进行文献检索。符合条件的队列研究和病例对照研究需评估生物标志物对免疫功能低下儿童细菌、病毒或真菌感染的预测能力,并与传统微生物学检查进行比较。若能单独评估儿科数据,则纳入包含成年患者的研究。收集了关于感染、发热、中性粒细胞减少症的定义以及预测值的数据。使用诊断准确性研究质量评估-2工具评估偏倚风险。
纳入了52项研究,涉及7059名儿童的13939次发热发作。其中,92.2%的研究对象为癌症患者(n = 48),15.7%的研究还纳入了造血干细胞移植患者(n = 8)。共研究了43种生物标志物,其中6种(CRP、PCT、IL-8、IL-6、IL-10和TNFα)在多项研究中被发现与入院时的细菌感染显著相关,并提供了预测数据。关于病毒和真菌感染预测的文献非常有限。八项研究比较了C反应蛋白(CRP)和降钙素原(PCT),其中五项研究显示PCT具有优势。六项、四项和一项研究分别将IL-6、IL-8和IL-10与CRP进行了比较,诊断优势结果不一。未发现比较PCT与IL-6、IL-8或IL-10的明显优势生物标志物。
所研究的生物标志物、临界值和使用的定义存在很大异质性,从而使分析变得复杂。关于非恶性疾病的免疫功能低下儿童和非细菌感染的文献稀少。尚无关于新型诊断方法的文献。我们在本研究人群中阐述了准确诊断发热的挑战以及对改进生物标志物和临床决策工具的需求。